Top

Published in:

01-11-2015 | Diagnostic Neuroradiology

Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging

Authors: Leonard Sunwoo, Seung Hong Choi, Roh-Eul Yoo, Koung Mi Kang, Tae Jin Yun, Tae Min Kim, Se-Hoon Lee, Chul-Kee Park, Ji-hoon Kim, Sun-Won Park, Chul-Ho Sohn, Jae-Kyung Won, Sung-Hye Park, Il Han Kim

Published in: Neuroradiology | Issue 11/2015

Abstract

Introduction

The aim of this study is to investigate perfusion characteristics of glioblastoma with an oligodendroglioma component (GBMO) compared with conventional glioblastoma (GBM) using dynamic susceptibility contrast (DSC) perfusion magnetic resonance (MR) imaging and microvessel density (MVD).

Methods

The study was approved by the institutional review board. Newly diagnosed high-grade glioma patients were enrolled (n = 72; 20 GBMs, 14 GBMOs, 19 anaplastic astrocytomas (AAs), 13 anaplastic oligodendrogliomas (AOs), and six anaplastic oligoastrocytomas (AOAs)). All participants underwent preoperative MR imaging including DSC perfusion MR imaging. Normalized cerebral blood volume (nCBV) values were analyzed using a histogram approach. Histogram parameters were subsequently compared across each tumor subtype and grade. MVD was quantified by immunohistochemistry staining and correlated with perfusion parameters. Progression-free survival (PFS) was assessed according to the tumor subtype.

Results

GBMO displayed significantly reduced nCBV values compared with GBM, whereas grade III tumors with oligodendroglial components (AO and AOA) exhibited significantly increased nCBV values compared with AA (p < 0.001). MVD analyses revealed the same pattern as nCBV results. In addition, a positive correlation between MVD and nCBV values was noted (r = 0.633, p < 0.001). Patients with oligodendroglial tumors exhibited significantly increased PFS compared with patients with pure astrocytomas in each grade.

Conclusion

In contrast to grade III tumors, the presence of oligodendroglial components in grade IV tumors resulted in paradoxically reduced perfusion metrics and MVD. In addition, patients with GBMO exhibited a better clinical outcome compared with patients with GBM.

Tortosa A, Vinolas N, Villa S, Verger E, Gil JM, Brell M, Caral L et al (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97:1063–1071CrossRefPubMed

Kanno H, Nishihara H, Narita T, Yamaguchi S, Kobayashi H, Tanino M, Kimura T et al (2012) Prognostic implication of histological oligodendroglial tumor component: clinicopathological analysis of 111 cases of malignant gliomas. PLoS One 7, e41669PubMedCentralCrossRefPubMed

van den Bent M, Chinot OL, Cairncross JG (2003) Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro Oncol 5:128–138PubMedCentralPubMed

Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY (2012) Primary brain tumours in adults. Lancet 379:1984–1996CrossRefPubMed

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343PubMedCentralCrossRefPubMed

van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350CrossRefPubMed

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralCrossRefPubMed

Wang Y, Li S, Chen L, You G, Bao Z, Yan W, Shi Z et al (2012) Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol 14:518–525PubMedCentralCrossRefPubMed

Salvati M, Formichella AI, D’Elia A, Brogna C, Frati A, Giangaspero F, Delfini R et al (2009) Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol 94:129–134CrossRefPubMed

10.

Laxton RC, Popov S, Doey L, Jury A, Bhangoo R, Gullan R, Chandler C et al (2013) Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Neuro Oncol 15:1635–1643PubMedCentralCrossRefPubMed

11.

Appin CL, Gao J, Chisolm C, Torian M, Alexis D, Vincentelli C, Schniederjan MJ et al (2013) Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics. Brain Pathol 23:454–461CrossRefPubMed

12.

Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR, Fitzek MM et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 25:214–221PubMed

13.

Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ et al (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 26:266–273PubMed

14.

Saito T, Yamasaki F, Kajiwara Y, Abe N, Akiyama Y, Kakuda T, Takeshima Y et al (2012) Role of perfusion-weighted imaging at 3T in the histopathological differentiation between astrocytic and oligodendroglial tumors. Eur J Radiol 81:1863–1869CrossRefPubMed

15.

Emblem KE, Scheie D, Due-Tonnessen P, Nedregaard B, Nome T, Hald JK, Beiske K et al (2008) Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. AJNR Am J Neuroradiol 29:1664–1670CrossRefPubMed

16.

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMed

17.

Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR (1996) High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 36:715–725CrossRefPubMed

18.

Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27:859–867PubMed

19.

Bjornerud A, Sorensen AG, Mouridsen K, Emblem KE (2011) T1- and T2*-dominant extravasation correction in DSC-MRI: part I—theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab 31:2041–2053PubMedCentralCrossRefPubMed

20.

Tozer DJ, Jager HR, Danchaivijitr N, Benton CE, Tofts PS, Rees JH, Waldman AD (2007) Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 20:49–57CrossRefPubMed

21.

Kang Y, Choi SH, Kim YJ, Kim KG, Sohn CH, Kim JH, Yun TJ et al (2011) Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging—correlation with tumor grade. Radiology 261:882–890CrossRefPubMed

22.

Scheie D, Andresen PA, Cvancarova M, Bo AS, Helseth E, Skullerud K, Beiske K (2006) Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors. Am J Surg Pathol 30:828–837CrossRefPubMed

23.

Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC et al (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490–498PubMedCentralCrossRefPubMed

24.

Hirai T, Murakami R, Nakamura H, Kitajima M, Fukuoka H, Sasao A, Akter M et al (2008) Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 29:1505–1510CrossRefPubMed

25.

Jain R, Poisson L, Narang J, Gutman D, Scarpace L, Hwang SN, Holder C et al (2013) Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology 267:212–220PubMedCentralCrossRefPubMed

26.

Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479CrossRefPubMed

27.

Ren X, Cui X, Lin S, Wang J, Jiang Z, Sui D, Li J et al (2012) Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients. PLoS One 7, e32764PubMedCentralCrossRefPubMed

28.

Eoli M, Bissola L, Bruzzone MG, Pollo B, Maccagnano C, De Simone T, Valletta L et al (2006) Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 119:84–90CrossRefPubMed

29.

Mizoguchi M, Yoshimoto K, Ma X, Guan Y, Hata N, Amano T, Nakamizo A et al (2012) Molecular characteristics of glioblastoma with 1p/19q co-deletion. Brain Tumor Pathol 29:148–153CrossRefPubMed

30.

He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P et al (2001) Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60:863–871PubMed

31.

Jenkinson MD, Smith TS, Joyce KA, Fildes D, Broome J, du Plessis DG, Haylock B et al (2006) Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 48:703–713PubMedCentralCrossRefPubMed

32.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773PubMedCentralCrossRefPubMed

33.

Ha SY, Kang SY, Do IG, Suh YL (2013) Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. J Neurooncol 112:439–448CrossRefPubMed

34.

Labussiere M, Sanson M, Idbaih A, Delattre JY (2010) IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist 15:196–199PubMedCentralCrossRefPubMed

35.

Sadeghi N, D’Haene N, Decaestecker C, Levivier M, Metens T, Maris C, Wikler D et al (2008) Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol 29:476–482CrossRefPubMed

36.

Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41–51CrossRefPubMed

37.

Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, Turnbull DH (2003) Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 49:848–855CrossRefPubMed

38.

Jain R, Gutierrez J, Narang J, Scarpace L, Schultz LR, Lemke N, Patel SC et al (2011) In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol 32:388–394CrossRefPubMed

Title: Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging
Authors: Leonard Sunwoo
Seung Hong Choi
Roh-Eul Yoo
Koung Mi Kang
Tae Jin Yun
Tae Min Kim
Se-Hoon Lee
Chul-Kee Park
Ji-hoon Kim
Sun-Won Park
Chul-Ho Sohn
Jae-Kyung Won
Sung-Hye Park
Il Han Kim
Publication date: 01-11-2015
Publisher: Springer Berlin Heidelberg
Published in: Neuroradiology / Issue 11/2015
Print ISSN: 0028-3940
Electronic ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-015-1569-6

At a glance: The STEP trials

Springer Medicine

Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2015

European Society of Neuroradiology (ESNR)

Iron deposition influences the measurement of water diffusion tensor in the human brain: a combined analysis of diffusion and iron-induced phase changes

Contrast-enhanced angiographic cone-beam computed tomography without pre-diluted contrast medium

Alterations in white matter volume and its correlation with clinical characteristics in patients with generalized anxiety disorder

Functional hemispherectomy: postoperative motor state and correlation to preoperative DTI

Arterial spin-labeling MR imaging of cerebral hemorrhages